Accelr8 Announces Collaboration Agreement With Promega

    DENVER, Oct. 17 /PRNewswire-FirstCall/ -- Accelr8 Technology Corporation
 (Amex:   AXK) announced today the signing of an agreement with Promega
 Corporation regarding Accelr8's proprietary OptiChem(R) surface chemistry for
 use in microarraying slides.  The agreement will allow for exploration of new
 techniques in microarray research using Accelr8 and Promega technologies.
     According to David Howson, Accelr8's president, "This agreement represents
 another event for Accelr8 in licensing out our technology components in the
 microarraying space."
     "We're gratified that Promega evaluated the alternatives and chose
 OptiChem because of its performance advantages.  We are also pleased to be
 associated with Promega because of their well-deserved reputation for
 excellence," said Howson.
     Microarray techniques allow researchers to study massive numbers of
 biomolecules in parallel.  The technology is based on placing thousands of
 different types of biomolecules onto a surface such as a glass microarray
 slide.  Microarrays have already had a major impact in fields ranging from
 cancer research to agriculture, and is rapidly moving from a discovery
 research tool to broader applications in medical diagnostics.  Accelr8's
 OptiChem coatings provide unique performance advantages that help to make
 OptiChem-coated slides an enabling component of next generation microarrays.
     The ongoing revenues from licensing occur in parallel with Accelr8's
 primary business focus in developing the BACcelr8r(TM) rapid bacterial
 analysis system.  Accelr8  intends the BACcelr8r to become the world's first
 diagnostic system to provide complete bacterial antibiotic resistance strain
 identification in 8 hours or less.  Conventional culturing typically delays
 lab results from one to three days, which is inadequate for best management of
 rapidly progressing, life-threatening infections in critically ill patients.
 
     About Accelr8
     Accelr8 Technology Corporation (www.accelr8.com) is a developer of
 innovative materials and instrumentation for advanced applications in medical
 instrumentation, basic research, drug discovery, and bio-detection.  In
 addition to its microarraying products, Accelr8 is also developing a rapid
 clinical pathogen platform, the BACcelr8r(TM), based on its innovative surface
 coatings, assay processing, and detection technologies.
 
 

SOURCE  Accelr8 Technology Corporation